Synapsoft logo
AI Insights from Disclosures
Searching...
Eutilex Co.,Ltd. 263050
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Eutilex Co.,Ltd. was founded in 2015 and engages in research and development based on immuno-oncology therapeutics, including cell and gene therapies (CGT) such as CAR-T and antibody therapeutics. EU307, one of the company's key pipelines, is a fourth-generation Armored CAR-T therapy that targets GPC3, which is highly expressed in solid tumors, particularly liver cancer, and expresses the immune-activating cytokine IL-18.
Representative Director 권병세, 안용섭 (각자대표이사)
Founded February 27, 2015
Corporation Type KOSDAQ
Industry Classification Manufacture of medicinal chemicals
Corporate number 28501-0287959
Business number 863-86-00031
Phone Number 02-3402-7314
Fax Number 02-3402-7399
Website www.eutilex.com
Company Address 58 Gasan digital 1-ro, Geumcheon-gu, Seoul
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant